Emalex Biosciences Announces $250 Million Financing Round to Advance Investigational New Drug for Tourette Syndrome

Clinical stage biopharmaceutical company completes upsized, oversubscribed Series D financing from leading life sciences investors CHICAGO, Nov. 3, 2022 -- (Healthcare Sales & Marketing Network) -- Emalex Biosciences announced the closing of an upsized... Biopharmaceuticals, Neurology, Venture Capital Emalex Biosciences, ecopipam, Tourette Syndrome
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news